NEW YORK — Moderna announced on Thursday it is working a single vaccine that combines a booster dose against COVID-19 with its experimental flu shot. The company said it hopes to eventually add vaccines it is working on for respiratory syncytial virus and other respiratory diseases as an annual shot. “We believe this is a
CAMBRIDGE, Mass. — Moderna announced that the first adolescent participants have been dosed in the Phase 2/3 study of mRNA-1273, the company’s vaccine candidate against COVID-19, in adolescents ages 12 to less than 18. The study is being conducted in collaboration with the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of
CAMBRIDGE, Mass.— Moderna announced that the U.S. government has secured 100 million doses of mRNA-1273 as part of the U.S. government’s goal of securing early access to safe and effective COVID-19 vaccines for the American people. The award of up to $1.525 billion is for the manufacturing and delivery of 100 million doses of mRNA-1273
